The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
about
Alleviating anemia and thrombocytopenia in myelofibrosis patients.Safety considerations when treating myelofibrosis.Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trialIdentification of AIM2 as a downstream target of JAK2V617F.Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.Ruxolitinib dose management as a key to long-term treatment success.Myelofibrosis: an update on drug therapy in 2016.Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidenceA spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician's perspective.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
P2860
Q33430113-1AC8E728-47E1-4AA9-A767-103B77FDCD0DQ33432285-7507695B-2C2B-485B-9C4D-A46F694C9B01Q33432637-69E8F794-5DC1-4DDC-8679-18CA43F511B1Q36513561-485BDA49-7DFF-4605-86C7-1B40DC202298Q38646051-22C8387B-5089-4B38-B46A-95E012342AD9Q38938939-A4ED75C9-1215-4F98-A5A9-BEF1AC3713DCQ38989215-F2E18619-4B3A-4383-9EFE-74B1F3A412B4Q39554738-F9739054-1000-48CA-B64D-6745D909063EQ47813570-995CD527-79BB-406A-8C63-93A8ACDAA852Q47815810-7CF2623E-7D14-4525-9588-D479126A1297Q48109284-10FD85B1-DC39-46E5-B5CB-C6E893ADD704Q51111145-5715CAB6-FB58-4C9C-B884-7EF8AEBFD52EQ52813540-E1111291-8A39-4624-A87F-030FCCF949F7Q53064328-7CD3FEFF-EBD8-4885-B870-459FF9B630E2
P2860
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
type
label
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
prefLabel
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
P2093
P2860
P1476
The use of erythropoiesis-stim ...... he treatment of myelofibrosis.
@en
P2093
Christian Recher
Claire N Harrison
Dietger Niederwieser
Heinz Gisslinger
Hilde Demuynck
Koen Theunissen
Mari McQuitty
Mary Frances McMullin
Nadja Jäkel
Prashanth Gopalakrishna
P2860
P2888
P356
10.1186/S40164-015-0021-2
P577
2015-09-15T00:00:00Z
P5875
P6179
1041228057